Downstream Issues Still Beset Production
To Protect the Bottom Line, Biomanufacturers Invest in Downstream Purification Technology
GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
10 Takeover Targets of 2016
Which Biopharmas Do Wall Street Watchers View As Top Buyout Candidates?
For full access to this article login to GEN Select now.
Systems Biology Alters Drug Development
Omics Tools Revitalize Field, but Deciphering High-throughput Data Is Still a Major Obstacle
- Research and development costs by pharmaceutical companies rose to an estimated $55.2 billion in 2006, with costs to develop a biologic drug reaching $1.2 billion. The potential of the Human Genome Project has yet to be fully realized, but many companies are starting to embrace systems biology as a ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.